5-(4-fluorophenyl)-2-(2-iodophenylamino)-1,3,4-thiadiazole

5-(4-fluorophenyl)-2-(2-iodophenylamino)-1,3,4-thiadiazole, also referred to as compound B3, is a synthetic small molecule designed as a nonsteroidal aromatase inhibitor. It features a 1,3,4-thiadiazole core substituted with a fluorophenyl group and an iodophenylamino moiety. The compound demonstrates selective cytotoxic activity against estrogen-dependent breast cancer cells, such as the MCF-7 line, while showing minimal effect on estrogen-independent cells like MDA-MB-231. Its mechanism of action involves binding to the active site of aromatase (CYP19A1), the enzyme responsible for the rate-limiting step in estrogen biosynthesis, thereby depriving hormone-sensitive tumors of the estrogens required for growth. Currently in the early stages of research, it represents a potential scaffold for the development of new endocrine therapies for breast cancer.